At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Poor Risk Recurrent Hodgkin's Disease
In Brief
A Phase 2 clinical trial evaluating filgrastim, busulfan, and 5 other interventions for Lymphoma. Completed, enrolled 42 participants across 1 site.
Detailed Summary
RATIONALE: Giving two autologous stem cell transplants (one after the other) may be an effective treatment for Hodgkin's lymphoma. PURPOSE: This phase II trial is studying how well giving two autologous stem cell transplants works in treating patients with progressive or recurrent Hodgkin's lymphoma.
Study Details
Timeline
Interventions
480 mcg beginning day +5
11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
60 mg/kg IV over 2 hours x 2 days
60 mg/kg, IV
150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
autologous-autologous tandem hematopoietic stem cell transplantation
radiation therapy